Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Fenn
G C
GC
Medical Department, Pfizer Australia, Sydney, New South Wales, Australia.
Grobler
M
M
Schaffer
D
D
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000201:enzymology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D016861:Cyclooxygenase Inhibitors